Two treatments with combined mother cells, promising treatment for type 1 diabetes.

Mixing a technique similar to that of Dr.zhao to re-educate the immune system so that it does not attack beta cells, with the patient's own stem cell injection in the pancreas, Dr. Adeeb al-Zoubi of the University of Ilinois,He affirmed at a conference, having managed to free 4 treaties from insulin injections.One for months and the other 3 for 2 years or more.And they never used anti-recreational drugs.

Link

As the link is in English, I copy the text translated automatically.

Practical Cure Project Update: Stem Cells Arabia

September 28, 2017

SUMMARY:

Stem Cells Arabia is one of the eleven T1D Practical Cure currently cure projects with human beings.
An I / II phase trial is currently registered in clinicaltrials.gov and is recruiting established T1D patients.
The supply of islet cells is treated with a stem cell treatment and cell protection is recycling white blood cells.
Although the first results seem promising, they have not been reviewed or published in a medical magazine.Therefore, until it is verified, all the results claimed must be read with caution.
This is the fifth of a series of reports that detail individual research projects currently in human beings with the potential to offer practical healing.It provides an update on the type I diabetes project in Stem Cells Arabia and presents an interview with the Director General of Arabic Research and Cells, Dr. Adeeb Al-Zoubi.Stem Cells Arabia is a private company based in Amman, Jordan.

This report was written in collaboration with Joshua Levy.You can find the Joshua Diabetes Information Blog here: Link

Research Summary

Stem Cells Arabia developed and is currently testing the Jordanian method for the treatment of diabetes.The method uses the patient's own blood, which is subjected to two separate treatments before being returned to the patient.The treatment is minimally invasive and does not require general anesthesia or surgery.

The procedure is as follows:

The blood of the patient T1D is extracted and processed to isolate white stem cells and blood cells (lymphocytes and monocytes).
First, stem cells are isolated from other contaminating blood cells through a purification process that produces highly pure stem cells, guaranteeing high regeneration and differentiation capacities.
Purified stem cells are transplanted in the most active pancreatic areas in insulin production, where they can grow in beta cells of insulin producers and completely functional alpha regulation cells.
Second, white blood cells are treated with mesenchymal stem cells of the umbilical cord (this approach is similar to Dr. Zhao's stem cell educator project at the Medical Center of the University of Hackensack.) Click here to read the reportof JDCA)
The theory is that once treated, white blood cells will no longer attack insulin producing cells that produce insulin.In addition, researchers expect these treated cells to train the remaining white blood cells in the patient.
Results of the pilot study on human essays (claimed by PI, unpublished or pairs)

In 2015, Stem Cell Arabia completed a pilot study of four people from patients who had established T1D for more than three years.Al-Zoubi states that three out of four patients achieved the independence of insulin and the fourth was able to significantly reduce the necessary external insulin amount.

After the initial treatment of blood and reinfusion, the procedure took an average of three to six months before the complete benefits were obtained.Three of the patients were able to stop using insulin completely and remained independent of insulin for two full years before Al-Zoubi lost contact with them.The fourth patient was out of insulin at 55 days after treatment for nine months.Then, he returned to insulin at a much more doseLow (0.1 U / Kg post-treatment, compared to 1.0 U / kg pretreatment) and is now in a single daily dose of 0.1 U / Kg.

If they are exact and credible, these are great results, but they should be read with caution until they are published and reviewed in pairs.When asked if Stem Cells Arabia plans to publish Al-Zoubi replied: "No, we are considering presenting a patent about this method. Our shareholders believe that we could have discovered something worthy of being presented for a patent."The JDCA encourages Al-Zoubi to put patients first and officially share their results with the scientific community T1D as soon as possible.

Current human test:

Stem Cells Arabia is recruiting for an I / II phase trial of 100 people in Amman, Jordan with the aim of demonstrating security and efficiency in children and adults from 8 to 55 years with established T1d (more than 12 months from diagnosis).The essay began in February 2014 and so far has registered 30 patients who have started treatment.The trail continues to recruit patients and lists a possible recruitment size of 100 patients in clinicaltrials.gov, but the size will depend on the amount of funds that Stem Cells Arabia can ensure.The estimated completion date is January 2019 and patients will be followed for up to five years.

Another one, and another, and another ...

It is clear that it is probably nothing, like many other similar news.
However, I have hope that there are so many people investigating.At some point someone will get from the laboratory to an effective cure for patients.Science has achieved it with many other diseases, sooner or later with this.

Sounds to me ...,

Fernandog said:
another, and another, and another ...

I would say that it is the first study that claims to release human patients without using anti-recharge drugs.

Those who always come out in the media are only mice or use immunosuppressants.